Combination therapy for malignant peripheral nerve sheath tumors

Tech ID: T-020000

Technology Description

Researchers in Angela Hirbe’s lab at Washington University have developed a method of treating malignant peripheral nerve sheath tumors (MPNSTs) with a combination of inhibitors. The most effective therapy is to combine an inhibitor of TYK2 with a MEK inhibitor.

MPNSTs are often associated with Neurofibromatosis Type 1 or as a secondary complication of radiation therapy. Despite multiple therapeutic options, 50% of patients see a recurrence.

Stage of Research

The researchers have tested the combination of TYK2 and MEK inhibitors on MPNST cells in vitro and on an NF1 model in vivo.

Applications

  • Malignant peripheral nerve sheath tumors (MPNSTs)

Key Advantages

  • Increases response to MEK inhibitor

Patents: Pending

Related Web Links: Hirbe Profile & Lab

Create a Collection
Creating...